Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered EP102 Monotherapy in Participants With Advanced Solid Tumors

NCT07163325 is registered in ClinicalTrials.gov with Epics Therapeutics as lead sponsor.

NCT NCT07163325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07163325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered EP102 Monotherapy in Participants With Advanced Solid Tumors
Lead sponsor
Epics Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
July 24, 2025
Completion date
November 30, 2028
Enrollment
48 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor (phase 1)